May 2018｜Mads Krogsgaard Thomsen, CSO of Novo Nordisk, considers the potential of stem cell-based therapies to cure type 1 diabetes and other chronic diseases
April 2018｜CEO, Lars Fruergaard Jørgensen, reflects on the challenge of providing access to care among vulnerable populations displaced by conflict
April 2018｜Meet Alvin Moustgaard, one of seven colleagues in our employment programme for people living with autism spectrum disorder.
February 2018｜Lotte Bjerre Knudsen, Scientific Vice President at Novo Nordisk, discovered the molecule liraglutide and oversaw its journey from “underdog candidate” to a treatment for more than a million people with diabetes and obesity.
December 2017｜Novo Nordisk Chief science officer Mads
Krogsgaard Thomsen reflects on the past, present and future of insulin
in a tablet.
Oral insulin remains the ‘Holy Grail’ of diabetes
November 2017｜President and chief executive officer of Novo
Nordisk, Lars Fruergaard Jørgensen on why the definition of obesity is
just the beginning of a broader, more significant discussion.
Changing the conversation about obesity
September 2017｜Simone, an employee of Novo Nordisk, reflects on
her perpetual battles with type 2 diabetes, heart disease and
Life with type 2 diabetes together with heart disease
September 2017｜With millions displaced by war, business has a
key role in helping refugees integrate, contribute and flourish in
Our role in helping refugees integrate and contribute
September 2017｜Can your peers help prevent type 2 diabetes?
Henriette Curtz Jansen from Copenhagen municipality thinks so and
shares how peer networks have been successful in Denmark.
Type 2 diabetes networks in Copenhagen